Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …

Purpose The pharmacology, efficacy, safety, and dosing/administration of new and
emerging therapies for the treatment of multiple myeloma are summarized. Summary There …

The use of bispecific antibodies as T cell engagers can bypass the normal T cell receptor-
major histocompatibility class interaction, redirect the cytotoxic activity of T cells, and lead to …

The delivery of bispecific antibodies (BsAbs) targeting B‐cell maturation antigen (BCMA)
and CD3 using the gene therapy approach is a promising alternative for BsAb administration …

The use of bispecific antibodies as T cell engagers can bypass the normal TCR-MHC
interaction, redirect the cytotoxic activity of T-cells, and lead to highly efficient tumor cell …